Lutathera Approval History
FDA Approved: Yes (First approved January 26, 2018)
Brand name: Lutathera
Generic name: lutetium Lu 177 dotatate
Dosage form: Injection
Company: Advanced Accelerator Applications S.A.
Treatment for: Gastroenteropancreatic Neuroendocrine Tumors
Lutathera (lutetium Lu 177 dotatate) is a Lu-177-labeled somatostatin analogue indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Development History and FDA Approval Process for Lutathera
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.